1
|
Zhu W, Harvey S, Macura KJ, Euhus DM and
Aremov D: Invasive breast cancer preferably and predominantly
occurs at the interface between fibroglandular and adipose tissue.
Clin Breast Cancer. 17:e11–e18. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Alipour S, Jannat F and Hosseini L:
Teaching breast cancer screening via text messages as part of
continuing education for working nurses: A case-control study.
Asian Pac J Cancer Prev. 15:5607–5609. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Agnihotri N, Kumar S and Mehta K: Tissue
transglutaminase as a central mediator in inflammation-induced
progression of breast cancer. Breast Cancer Res. 15:2022013.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Wang J, Xi C, Yang X, Lu X, Yu K, Zhang Y
and Gao R: LncRNA WT1-AS inhibits triple-negative breast cancer
cell migration and invasion by downregulating transforming growth
factor-β1. Cancer Biother Radiopharm. 34:671–675. 2019.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Takai E, Tsukimoto M and Kojima S:
TGF-β1 downregulates COX-2 expression leading to
decrease of PGE2 production in human lung cancer A549 cells, which
is involved in fibrotic response to TGF-β1. PLoS One.
8:e763462013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Shao M, Cao L, Shen C, Satpathy M,
Chelladurai B, Bigsby RM, Nakshatri H and Matei D:
Epithelial-to-mesenchymal transition and ovarian tumor progression
induced by tissue transglutaminase. Cancer Res. 69:9192–9120. 2009.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Humbert L, Ghozlan M, Canaff L, Tian J and
Lebrun JJ: The leukemia inhibitory factor(LIF) and p21 mediate the
TGFβ tumor suppressive effects in human cutaneous melanoma. BMC
Cancer. 15:2002015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cao L, Shao M, Schilder J, Guise T,
Mohammad KS and Matei D: Tissue transglutaminase links TGF-β,
epithelial to mesenchymal transition and a stem cell phenotype in
ovarian cancer. Oncogene. 31:2521–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Efferth T, Konkimalla VB, Wang YF,
Sauerbrey A, Meinhardt S, Zintl F, Mattern J and Volm M: Prediction
of broad spectrum resistanc-e of tumors towards anticancer drugs.
Clin Cancer Res. 14:2405–2412. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Segers-Nolten IM, Wilhelmus MM, Veldhuis
G, van Rooijen BD, Drukarch B and Subramaniam V: Tissue
transglutaminase modulates alpha-synuclein oligomeri-zation.
Protein Sci. 17:1395–1402. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Schmid AW, Chiappe D, Pignat V, Grimminger
V, Hang I, Moniatte M and Lashuel HA: Dissecting the mechanisms of
tissue transglutaminase-induced cross-linkingof alpha-synuclein:
Implications for the pathogenesis of parkinson disease. J BiolChem.
284:13128–13142. 2009.
|
12
|
Assi J, Srivastava G, Matta A, Chang MC,
Walfish PG and Ralhan R: Transglutaminase 2 overexpression in tumor
stroma identifies invasive ductal carcinomas of breast at high risk
of recurrence. PLoS One. 8:e744372013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Király R, Thangaraju K, Nagy Z, Collighan
R, Nemes Z, Griffin M and Fésüs L: Isopeptidase activity of human
transglutaminase 2: Disconnection from transamidation and
characterization by kinetic parameters. Amino Acids. 48:31–40.
2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhao G, Zhang ZQ, Zhang B, Luo M, Sun YW
and Wu ZY: Down-Regulation of TG2 expression by RNAi inhibits HSC
proliferation and attenuates liver fibrosis. Int J Clin Exp Pathol.
4:513–520. 2011.PubMed/NCBI
|
15
|
Alves MJ, Figuerêdo RG, Azevedo FF,
Cavallaro DA, Neto NI, Lima JD, Matos-Neto E, Radloff K, Riccardi
DM, Camargo RG, et al: Adipose tissue fibrosis in human cancer
cachexia: The role of TGF-β pathway. BMC Cancer. 17:1902017.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang YP, Cao SY, Ma JY, Wang LQ and Wang
BF: The change and significance of coagulation activity in
bleomycin-induced lung fibrosis in rats. Zhonghua Jie He He Hu Xi
Za Zhi. 28:541–544. 2005.(In Chinese). PubMed/NCBI
|
17
|
Vesprini D, Narod SA, Trachtenberg J,
Crook J, Jalali F, Preiner J, Sridhar S and Bristow RG: The
therapeutic ratio is preserved for radiotherapy or cisplatin
treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J.
5:E31–E35. 2011. View Article : Google Scholar : PubMed/NCBI
|